9:55am ET
Health and Healthcare
Eli Lilly Stumbles on Discontinued Drug Trial
Eli Lilly is suffering after bad news about its evacetrapib for high-risk atherosclerotic cardiovascular disease.
Jon C. Ogg
Companies
/Healthcare
Lilly(Eli) & Company
$1,150.99
▼ $19.15 (−1.64%) today
Markets closed · 12:28am ET
LLY Coverage
Page 36 Jon C. Ogg 11:20am ET
Health and Healthcare
Why Cholesterol and Alzheimer’s Could Drive Eli Lilly Shares Much Higher
Credit Suisse sees solid upside in this company Eli Lilly as the result of a strong pipeline, with its Alzheimer's candidate as a potential blockbuster.
Chris Lange 8:50am ET
Investing
Top Analyst Upgrades and Downgrades: AT&T, BioCryst, Eli Lilly, Facebook, Flextronics, Gap, Tesla and More
Friday's top analyst upgrades, downgrades and initiations include AT&T, BioCryst Pharmaceuticals, Eli Lilly, Facebook, Flextronics, Gap and Tesla Motors.
10:25am ET
Investing
UBS Makes Big Biotech and Pharmaceutical Additions to Equity Focus List
Wikimedia CommonsIf there was ever a time when investors are thrilled to see the calendar change it could be now. With the fourth quarter just starting, many are more than relieved to…
9:20am ET
Investing
4 Top Merrill Lynch US Defensive Stock Ideas for Q4
After the worst quarter in the stock market in four years, a new research report from Merrill Lynch includes the firm's top 10 U.S. ideas for the fourth quarter.
8:35am ET
Investing
Merrill Lynch Makes Changes to US 1 List Amid Market Turmoil
The market volatility has left all investors a touch shaken, but the chatter of a bear market and a collapse ring pretty hollow when the economy is not in recession.
9:45am ET
Health and Healthcare
Merrill Lynch Has 4 Pharma Stocks to Buy Against Political Chatter
One positive from the hammering the pharmaceutical stocks have taken is the Merrill Lynch analysts say investors have been given a golden opportunity to buy the top companies at much better prices.
11:45am ET
Health and Healthcare
Why Merrill Lynch Sees More Upside in Eli Lilly
Merrill Lynch reiterated a Buy rating and price objective on Eli Lilly after positive data on its Jardiance.
Chris Lange 9:25am ET
Investing
History Says Market Could Retest Lows: 4 Safe Stocks to Buy
The gut-wrenching drop back in August, when the Dow opened down 1,000 points and the indexes went through the first 10% correction in almost four years was, needless to say, an eye-opener…
8:25am ET
Investing
Top Analyst Upgrades and Downgrades: Aetna, Eli Lilly, Gilead, Royal Gold, Sirius XM and Many More
Friday’s top analyst upgrades, downgrades and initiations include Aetna, Eli Lilly, Gilead Sciences, Royal Gold and Sirius XM.
11:15am ET
Health and Healthcare
Eli Lilly Continues to Rise on Positive Jardiance Results
Eli Lilly shares got a solid boost in the market Thursday morning as the broad markets were selling off.
Chris Lange 8:35am ET
Investing
Merrill Lynch US 1 List Update: Momentum Stock Panera Bread Is Out
With Panera Bread out of the Merrill Lynch US 1 List, these dividend contrarian plays could make good sense now.
8:22am ET
Health and Healthcare
4 Top Pharma Stocks That Should Outperform Out To 2016
ThinkstockWith a very nervous market, and the end of summer doldrums upon us, it may be time to look for ideas that will make sense when the market heats back up in…
8:35am ET
Health and Healthcare
4 Large Cap Pharmaceutical Stocks to Buy on Strong Health Care Trends
24/7 Wall St. screened the Merrill Lynch health care universe and found four pharmaceutical stocks rated Buy with outstanding short-term and long-term potential.
11:05am ET
Health and Healthcare
How Much New Eli Lilly Product Launches Boosted the Bottom Line
Eli Lilly reported better-than-expected second-quarter earnings Thursday before the markets opened.
Chris Lange